| Similar Articles |
|---|
 |
The Motley Fool
March 26, 2008
Brian Lawler |
Take Two for Depomed The pharmaceutical starts another study for its proposed pain drug. The new study will double the size of patients enrolled and help reduce placebo effects.   |
The Motley Fool
August 9, 2007
Brian Lawler |
Depomed Is Distressed Depomed announces its distressing second-quarter financial results, with failed phase 3 studies and under-performing drugs. |
The Motley Fool
June 22, 2011
Brian Orelli |
Building on Pfizer's Blockbuster New data for an expanded indication for Lyrica. |
The Motley Fool
July 6, 2007
Brian Orelli |
Pain-Free Phase 2 Data Anesiva's pain medication is moving up the clinical trial ladder. The Adlea results are very promising, but investors should look at the state of the entire company before investing. |
The Motley Fool
September 6, 2007
Brian Lawler |
NeurogesX Feels No Pain Investors reward the drugmaker for positive study results. |
The Motley Fool
April 26, 2007
Mike Havrilla |
Xenoport Soothes Investors' Restless Hearts Shares surge on positive trial results of an experimental drug for restless legs. Investors, take note. |
The Motley Fool
September 18, 2009
Brian Orelli |
A 25% Stock Gain Will Ease Any Pain Glaxo and XenoPort's shingles drug gives the latter's shares a healthy boost. |
The Motley Fool
January 3, 2011
Brian Orelli |
Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure. |
The Motley Fool
January 31, 2011
Brian Orelli |
Drug Approved! Now Who's Going to Launch It? Depomed gets pain-free news from the FDA. |
The Motley Fool
March 4, 2010
Brian Orelli |
A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan. |
The Motley Fool
November 14, 2011
Brian Orelli |
Biotech Uncertainty = Big Upside Potential Aastrom's phase 2 and phase 3 trials don't match up. |
The Motley Fool
August 31, 2009
Brian Orelli |
Don't Let Dummy Pills Make You a Dummy Investor Instead of being scared that the sugar pill will perform better than expected, pharma investors should factor it in and require more information before investing in companies with drugs that may be affected by it.. |
The Motley Fool
January 19, 2011
Brian Orelli |
A Painfully Protracted Partner Depomed is in a bind. |
The Motley Fool
April 7, 2011
Brian Orelli |
Restless No Longer XenoPort and Glaxo get a delayed FDA approval. |
The Motley Fool
June 22, 2010
Dave Mock |
A Big Upgrade for DepoMed This bullish call comes from more than just one analyst. |
The Motley Fool
October 31, 2007
Brian Lawler |
Depomed Plays Hot Potato Following disappointing sales numbers, King Pharmaceuticals and Depomed terminate their marketing collaboration deal. |
Wired
August 24, 2009
Steve Silberman |
Placebos Are Getting More Effective. Drugmakers Are Desperate to Know Why. The fact that taking a faux drug can powerfully improve some people's health -- the so-called placebo effect -- has long been considered an embarrassment to the serious practice of pharmacology. |
The Motley Fool
May 16, 2007
Mike Havrilla |
Biotech Prospects for a Sizzling Summer Consider these biotech stocks to make your portfolio sizzle this summer. Advanced Life Sciences... Depomed... Theravance... etc. |
Nursing
October 2009
Yvonne D'Arcy |
Overturning barriers to pain relief in older adults This article will describe how to lower the barriers to effective pain control in older patients and provide practical tips for helping them receive the full benefit from pharmacologic and nonpharmacologic therapies. |
American Journal of Nursing
April 2010
Mary Curry Narayan |
Culture's Effects on Pain Assessment and Management When patients belong to a culture or speak a language that's different from that of their health care provider, the provider faces additional challenges in successfully assessing and managing the patients' pain. |
American Family Physician
February 1, 2005
Maizels & McCarberg |
Antidepressants and Antiepileptic Drugs for Chronic Non-Cancer Pain The development of newer classes of antidepressants and second-generation antiepileptic drugs has created unprecedented opportunities for the treatment of chronic pain. These drugs modulate pain transmission by interacting with specific neurotransmitters and ion channels. |
Nurse Practitioner
May 2012
Hammersla & Kapustin |
Peripheral Neuropathy: Evidence-based treatment of a complex disorder Peripheral neuropathy is a common and often progressive condition frequently seen in primary care. The chronic pain associated with PN, or neuropathic pain, can significantly diminish patients' quality of life and be challenging to treat. |
American Family Physician
October 1, 2001
Karl E. Miller |
Challenges in Pain Management at the End of Life Effective pain management in the terminally ill patient requires an understanding of pain control strategies. Ongoing assessment of pain is crucial and can be accomplished using various forms and scales... |
Nursing
June 2008
Yvonne D'arcy |
Nursing2008 Pain Management Survey Report See how your responses to this survey compare with those of nursing colleagues across the country and beyond. |
Salon.com
October 2, 2000
Lynn O'Dell |
Pain in the brain The good news? The hurt is all in your mind. The bad news? The hurt is all in your mind... |
American Journal of Nursing
December 2010
Baldridge & Andrasek |
Pain Assessment in People with Intellectual or Developmental Disabilities Nurses in all settings need to be knowledgeable about alternate pain assessment methods. |
Managed Care
October 2003
Martin Sipkoff |
Pain Management: Health Plans Need to Take Control Insurers have not focused much on chronic pain. They should. It presents a humanitarian and business opportunity. |
